Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581280 | 1.00 | MAOA (0.52) | MAOAMAOBOPRM1OPRL1GAA | |
| SCHEMBL1588016 | 1.00 | MAOA (0.52) | MAOAMAOBOPRM1OPRL1GAA | |
| SCHEMBL8347115 | 0.98 | MAOA (0.54) | MAOAMAOBOPRM1OPRL1GAA | |
| SCHEMBL156160 | 0.93 | MAOA (0.54) | MAOAMAOBOPRM1OPRL1GAA | |
| Formamide SCHEMBL28694742 | 0.88 | MAOA (0.47) | MAOAMAOBOPRM1OPRL1GAA | |
| SCHEMBL2864890 | 0.87 | MAOA (0.50) | MAOAMAOBOPRM1OPRL1GAA | |
| SCHEMBL18114517 | 0.87 | MAOA (0.45) | MAOAMAOBOPRM1OPRL1GAA | |
| SCHEMBL4896837 | 0.87 | GAA (0.51) | MAOAMAOBGAAALDH1A1KMT2A | |
| SCHEMBL10602994 | 0.87 | MAOA (0.50) | MAOAMAOBOPRM1OPRL1GAA | |
| SCHEMBL30613092 | 0.87 | ALDH1A1 (0.41) | MAOAMAOBOPRM1OPRL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 641 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119688896-B | Cell membrane bionic nano-recognition material and preparation method and application thereof | 陕西科技大学 | 2026-05-12 | — | — | CN | claimed |
| CN-119033823-B | Probiotic product and preparation method and application thereof | 南昌大学 | 2025-04-22 | — | — | CN | claimed |
| CN-119753095-A | Antibiotic resistance gene detection method for click chemistry coupling biosensing | 华东师范大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119688896-A | Cell membrane bionic nano-recognition material and preparation method and application thereof | 陕西科技大学 | 2025-03-25 | — | — | CN | claimed |
| CN-119033823-A | Probiotic product and preparation method and application thereof | 南昌大学 | 2024-11-29 | — | — | CN | claimed |
| CN-118759172-A | Preparation method of allophycocyanin immunofluorescence probe | 宝天生物科技（上海）有限公司 | 2024-10-11 | — | — | CN | claimed |
| US-20240327322-A1 | Crosslinked Polymers with Tunable Coefficients of Thermal Expansion | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC | 2024-10-03 | — | — | US | claimed |
| EP-3601609-B1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | CHARLES RIVER LABORATORIES INC (US) | 2024-07-03 | — | — | EP | claimed |
| CN-117327262-B | Responsive nano-drug carrier and preparation and application thereof | 中山大学附属第三医院 | 2024-06-14 | — | — | CN | claimed |
| US-20240181074-A1 | PEGYLATED T CELL ENGAGER WITH DUAL SPECIFICITIES TO CD3 AND CD19 | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2024-06-06 | — | — | US | claimed |
| EP-3274473-A1 | METHODS AND COMPOSITIONS FOR SINGLE MOLECULE COMPOSITION LOADING | Pacific Biosciences of California, Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| US-20180023115-A1 | Nanopore Detection of Target Polynucleotides From Sample Background | ONTERA INC. | 2018-01-25 | — | — | US | claimed |
| WO-2017173392-A1 | NANOPORE DISCRIMINATION OF TARGET POLYNUCLEOTIDES FROM SAMPLE BACKGROUND BY FRAGMENTATION AND PAYLOAD BINDING | Two Pore Guys, Inc. (US) | 2017-10-05 | — | — | WO | claimed |
| EP-3202424-A1 | KIT FOR FORMULATION OF LIPOSOMAL DOXORUBICIN MODIFIED WITH BIOACTIVE PEPTIDES FOR SELECTIVE TARGETING OF RECEPTORS OVEREXPRESSED BY CANCER CELLS | Invectors S.r.l. (IT) | 2017-08-09 | — | — | EP | claimed |
| US-20170209474-A1 | KIT FOR FORMULATION OF LIPOSOMAL DOXORUBICIN MODIFIED WITH BIOACTIVE PEPTIDES FOR SELECTIVE TARGETING OF RECEPTORS OVEREXPRESSED BY CANCER CELLS | INVECTORS S.R.L. (IT) | 2017-07-27 | — | — | US | claimed |
| WO-2017120536-A1 | POLYETHYLENIMINE (PEI)-POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | APG THERAPEUTICS, INC. (US) | 2017-07-13 | — | — | WO | claimed |
| WO-2016154345-A1 | METHODS AND COMPOSITIONS FOR SINGLE MOLECULE COMPOSITION LOADING | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2016-09-29 | — | — | WO | claimed |
| WO-2016154337-A2 | METHOD FOR IDENTIFICATION AND ENUMERATION OF NUCLEIC ACID SEQUENCES, EXPRESSION, SPLICE VARIANT, TRANSLOCATION, COPY, OR DNA METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, TERMINAL TRANSFERASE, AND SEQUENCING REACTIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-09-29 | — | — | WO | claimed |
| WO-2016126746-A1 | NANOPORE DETECTION OF TARGET POLYNUCLEOTIDES FROM SAMPLE BACKGROUND | Two Pore Guys, Inc. (US) | 2016-08-11 | — | — | WO | claimed |
| EP-0606344-B1 | SOLID-FORM ADDITIVE SYSTEMS DISPERSIBLE IN AQUEOUS MEDIA AND METHOD FOR THEIR PREPARATION | EASTMAN CHEM CO (US) | 1996-01-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240181074-A1 | PEGYLATED T CELL ENGAGER WITH DUAL SPECIFICITIES TO CD3 AND CD19 | CD4, CD2, CD22 | MAOA 4195/4885MAOB 1196/4885OPRM1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.